Focus Technology Co.Ltd(002315) independent director
Prior approval opinions on relevant matters
According to the guiding opinions on the establishment of independent director system in listed companies, the stock listing rules of Shenzhen Stock Exchange and the articles of association, as independent directors of the company, after careful review and full demonstration, We hereby give the following prior approval opinions on the announcement on the forecast of daily connected transactions in 2022 considered at the 20th meeting of the Fifth Board of directors of the company:
Prior approval opinions for daily related party transactions in 2022:
The daily related party transactions expected to occur between the company and related parties in 2022 are mainly:
The Focus Fund (hereinafter referred to as “Focus Fund”) is a wholly-owned investment in Nanjing Co., Ltd. (hereinafter referred to as “Focus Fund”) to increase the operating income of the focus fund management center, which is conducive to the investment of Nanjing Co., Ltd. (hereinafter referred to as “Focus Fund”) and collect reasonable management fees from the focus fund management center.
Jiangsu health worry free network technology Co., Ltd. (hereinafter referred to as “health worry free”) is a joint venture established by Focus Technology Co.Ltd(002315) around the Internet smart medical industry. It is a high-tech enterprise focusing on the information construction of public health and medical industry. Since its establishment, it has always been committed to developing software products and overall solutions with independent intellectual property rights in the fields of public health, regional medical informatization and Internet smart medicine, and providing diversified information services including system integration, software development, operation and maintenance for users in public health and medical industry at all levels. This transaction is the focus small loan of Focus Technology Co.Ltd(002315) holding subsidiary, which provides loan business.
The above transactions belong to the scope of normal business activities. The determination of transaction price comprehensively considers all relevant factors and embodies the principles of openness, fairness and impartiality. There is no damage to the interests of the company and minority shareholders, nor will it affect the independence of the company. Therefore, we agree to submit the proposal to the board of directors of the company for deliberation. When considering the specific items of the proposal, Mr. Shen Jinhua, a related director, shall withdraw from voting.
Independent directors: Geng Chengxuan, Luo Junzhou, Liu Xiaoxing February 17, 2022
